Story perspectives

New Drug Target May Halt Alzheimer's Progression

10/13/2025

49 9

Summary

Story summary

Researchers at Washington University School of Medicine found that disabling the circadian protein REV-ERB? may protect against Alzheimer's disease, as described in a Nature Aging study.
In mouse studies, blocking REV-ERB? reduced the accumulation of toxic tau and slowed neurodegeneration.
Deleting REV-ERB? increased NAD+ levels, a molecule crucial for brain health.
Inhibiting REV-ERB? with a promising drug produced similar protective effects, supporting potential therapy.

1 of 1

Story summary

Researchers at Washington University School of Medicine found that disabling the circadian protein REV-ERB? may protect against Alzheimer's disease, as described in a Nature Aging study.
In mouse studies, blocking REV-ERB? reduced the accumulation of toxic tau and slowed neurodegeneration.
Deleting REV-ERB? increased NAD+ levels, a molecule crucial for brain health.
Inhibiting REV-ERB? with a promising drug produced similar protective effects, supporting potential therapy.